Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review

References

• AndesDCraigWAIn vivo pharmacodynamic activity of the glycopeptide dalbavancinAntimicrob Agents Chemother20075116334217307987
   PubMed Web of Science ®Google Scholar
• BeltramettiFLazzariniABrunatiCProduction and characterizatio of monochlorinated and dechlorinated A40926 derivativesJ Antibiot2003567738214632287
   PubMed Web of Science ®Google Scholar
• BiedenbachDJRossJEFritscheTRActivity of dalbavancin tested against Staphylococcus spp and β-hemolytic Streptococcus spp isolated from 52 geographically diverse medical centers in the United StatesJ Clin Microbiol200745998100417215346
   PubMed Web of Science ®Google Scholar
• BowkerKENoelARMacGowanAPPharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic systemJ Antimicrob Chemother200658802516891629
   PubMed Web of Science ®Google Scholar
• BozdoganBEselDWhitenerCAntibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical CenterJ Antimicrob Chemother200352864814563898
   PubMed Web of Science ®Google Scholar
• BuckwalterMDowellJAPopulation pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptideJ Clin Pharmacol20054512798716239361
   PubMed Web of Science ®Google Scholar
• CampbellKCKellyETargovnikNAudiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibioticJ Am Acad Audiol2003141576812859140
   PubMedGoogle Scholar
• CandianiGAbbondiMBorgonoviMIn-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibioticJ Antimicrob Chemother1999441799210473224
   PubMed Web of Science ®Google Scholar
• CavaleriMRivaSValagussaAPharmacokinetics and excretion of dalbavancin in the ratJ Antimicrob Chemother200555Suppl 2ii31515750035
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention National Nosocomial Infections Surveillance (NNIS) SystemNNIS system report, data summary from January 1992 through June 2003, issued August 2003Am J Infect Control2003314819814647111
   PubMed Web of Science ®Google Scholar
• ChangFYPeacockJEJrMusherDM Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter studyMedicine2003b82333914530782
   PubMed Web of Science ®Google Scholar
• ChangSSieverDMHagemanJCInfection with Vancomycin-resistant Staphylococcus aureus containing the vanA resistance geneN Engl J Med2003a3481342712672861
   PubMed Web of Science ®Google Scholar
• CharlesPGWardPBJohnsonPDClinical features associated with bacteremia due to heterogenous vancomycin-intermediate Staphylococcus aureus Clin Infect Dis2004384485114727222
   PubMed Web of Science ®Google Scholar
• DarouicheROMansouriMDDalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivoJ Infect200550206915780414
   PubMed Web of Science ®Google Scholar
• DeresinskiSCounterpoint: Vancomycin and Staphylococcus aureus-an antibiotic enters obsolescenceClin Infect Dis2007441543817516396
   PubMed Web of Science ®Google Scholar
• DoernGVJonesRNPfallerMABacterial pathogens isolated from patients with skin and soft-tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America)Diagn Microbiol Infect Dis199934657210342110
   PubMed Web of Science ®Google Scholar
• DowellJABuckwalterMSeltzerEDalbavancin penetration into skin supports once weekly dosing. (Abstract 895)200515th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)2005, April 2–5Copenhagen, Denmark
   Google Scholar
• DowellJASeltzerEBuckwalterMThe Pharmacokinetics of Dalbavancin (DAL) in Subjects with Mild, Moderate or Severe Hepatic Impairment (HI)2004Abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy2004Washington, DC2
   Google Scholar
• DowellJASeltzerEStogniewMDalvavancin dosage adjustment not rcquired for patients with mild renal impariment (abstract P1224)Clin Microbiol Infect20039Suppl 1291
   Google Scholar
• FinchRGEliopoulosGMSafety and efficacy of glycopeptide antibioticsJ Antimicrob Chemother200555Suppl 2ii51315750036
   PubMed Web of Science ®Google Scholar
• FlammRKDraghiDCKarlowskyJAActivity of dalbavancin against clinical isolates of staphylococci and streptococci from the U.S. and Europe2004Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy2004Washington, DC, USA173
   Google Scholar
• FridkinSKHagemanJCMorrisonMMethicillin-resistant Staphylococcus aureus diseases in three communitiesN Engl J Med200535214364415814879
   PubMed Web of Science ®Google Scholar
• GoldsteinBPJonesRNFritscheTRMicrobiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infectionsDiagn Microbiol Infect Dis2006a5483716458124
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMMerriamCVIn vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteriaAntimicrob Agents Chemother20034719687112760876
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMWarrenYAIn vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infectionsAntimicrob Agents Chemother2006b502875916870792
   PubMed Web of Science ®Google Scholar
• GoldsteinBPDraghiDCSheehanDJBactericidal activity and resistance development profiling of dalbavancinAntimicrob Agents Chemother2007511150417220411
   PubMed Web of Science ®Google Scholar
• HiramatsuKAritakaNHanakiHDissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycinLancet1997350167039400512
   PubMed Web of Science ®Google Scholar
• JabesDCandianiGRomanoGEfficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection modelAntimicrob Agents Chemother20044811182315047510
   PubMed Web of Science ®Google Scholar
• JaureguiLEBabazadehSSeltzerERandomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infectionsClin Infect Dis20054114071516231250
   PubMed Web of Science ®Google Scholar
• JohnsonDMFritscheTRSaderHSEvaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactionsInt J Antimicrob Agents2006275576016698238
   PubMed Web of Science ®Google Scholar
• JonesRNBiedenbachDJJohnsonDMIn vitro evaluation of BI 397, a novel glycopeptide antimicrobial agentJ Chemother2001132445411450881
   PubMed Web of Science ®Google Scholar
• JonesRNFritscheTRSaderHSAntimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocolJ Chemother20051759360016433188
   PubMed Web of Science ®Google Scholar
• JonesRNSaderHSFritscheTRDalbavancin (DAL; formerly BI397) activity against selected populations of antimicrobial-resistant gram-positive pathogens. (Abstract 172)2003Abstract of the 41st Annual Meeting of the Infectious Diseases Society of America2003San DiegoIDSA
   Google Scholar
• KingMDHumphreyBJWangYFEmergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infectionsAnn Intern Med20061443091716520471
   PubMed Web of Science ®Google Scholar
• LefortAPavieJGarryLActivities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due Staphylococcus aureus to with or without reduced susceptibility to vancomycin and teichoplaninAntimicrob Agents Chemother2004481061414982811
   PubMed Web of Science ®Google Scholar
• LeightonAGottliebABDorrMBTolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteersAntimicrob Agents Chemother200448940514982787
   PubMed Web of Science ®Google Scholar
• LinGCreditoKEdnieLMAntistaphylococcal activity of dalbavancin, an experimental glycopeptideAntimicrob Agents Chemother200549770215673763
   PubMed Web of Science ®Google Scholar
• LipskyBABerendtARDeeryHGDiagnosis and treatment of diabetic foot infectionsClin Infect Dis20043988591015472838
   PubMed Web of Science ®Google Scholar
• MalabarbaACiabattiRGlycopeptide derivativesCurr Med Chem2001817597311562292
   PubMed Web of Science ®Google Scholar
• MareeCLDaumRSBoyle-VavraSCommunity-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infectionsEmerg Infect Dis2007132364217479885
   PubMed Web of Science ®Google Scholar
• MoelleringRCVancomycin-resistant EnterococciClin Infect Dis199826119699597252
   PubMed Web of Science ®Google Scholar
• MohrJFMurrayBEPoint: Vancomycin is not obsolete for treatment of infection caused by methicillin-resistant Staphylococcus aureus Clin Infect Dis2007415364217516395
   PubMed Web of Science ®Google Scholar
• MoranGJKrishnadasnAGorwitzRJMethicillin-resistant S. aureus infections among patients in the emergency departmentN Engl J Med20063556667416914702
   PubMed Web of Science ®Google Scholar
• NicolauDPSunHKSeltzerEPharmacokinetics of dalbavancin in plasma and skin blister fluidJ Antimicrob Chemother2007 epublished Jul 12, 2007
   PubMed Web of Science ®Google Scholar
• Pfizer IncDalbavancin [prescribing information]2007New York, NYPfizer Inc
   Google Scholar
• PopeSDRoeckerAMDalbavancin: a novel lipoglycopeptide antibacterialPharmacotherapy2006269081816803423
   PubMed Web of Science ®Google Scholar
• RaadIDarouicheRVazquezJEfficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogensClin Infect Dis2005403748015668859
   PubMed Web of Science ®Google Scholar
• SeltzerEDorrMBGoldsteinBPOnce-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infectionsClin Infect Dis200337129830314583862
   PubMed Web of Science ®Google Scholar
• SeyboldUKourbatovaEKJohnsonJGEmergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infectionsClin Infect Dis20064264765616447110
   PubMed Web of Science ®Google Scholar
• SieradzkiKRobertsRBHaberSWThe development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infectionN Engl J Med19993405172310021472
   PubMed Web of Science ®Google Scholar
• SievertDMBoultonMLStolzmanG Staphylococcus aureus resistant to vancomycin-United States, 2002MMWR Morb Mortal Wkly Rep200251565712139181
   PubMedGoogle Scholar
• SkhirtladzeKHutschalaDFleckTImpaired target site penetration of vancomycin in diabetic patients following cardiac surgeryAntimicrob Agents Chemother2006501372516569854
   PubMed Web of Science ®Google Scholar
• StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft-tissue infectionsClin Infect Dis2005411373140616231249
   PubMed Web of Science ®Google Scholar
• StreitJMFritscheTRSaderHSWorldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolatesDiagn Microbiol Infect Dis2004481374314972384
   PubMed Web of Science ®Google Scholar
• StreitJMSaderHSFritscheTRDalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogensDiagn Microbiol Infect Dis2005533071015922534
   PubMed Web of Science ®Google Scholar
• StryjewskiMESzczechLABejnajminDKJrUse of vancomycin or first-generation cephalosporins for the treatment of hemodialysis dependent patient with methicillin-susceptible Staphylococcus aureus bacteremiaClin Infect Dis200744190617173215
   PubMed Web of Science ®Google Scholar
• StyersDSheehanDJHoganPLaboratory-based surveillance of current antimicrobial patterns and trends among Staphylococcus aureus: 2005 status in the United StatesAnn Clin Microbiol Antimicrob20055216469106
   PubMedGoogle Scholar
• Technikova-DobrovaZDamianoFTrediciSMDesign of mineral medium for growth of Actinmadura sp. ATCC 39727, produce of the glycopeptide A40926: effects of calcium ions and nitrogen sourcesAppl Microbil Biotechnol2004656717
   PubMed Web of Science ®Google Scholar
• Van BambekeFVan LaethemYCourvalinPGlycopeptide antibiotics: from conventional molecules to new derivativesDrugs2004649133615101783
   PubMed Web of Science ®Google Scholar
• VossAMilatovicDWallrauch-SchwarzCMethicillin-resistant Staphylococcus aureus in EuropeEur J Clin Microbiol Infect Dis19941350558168564
   PubMed Web of Science ®Google Scholar
• WoodfordNNovel agents for the treatment of resistant gram-positive infectionsExpert Opin Investig Drugs20031211737
   PubMed Web of Science ®Google Scholar
• ZetolaNFrancisJFNuermbergerELCommunity-acquired methicillin-resistant Staphylococcus aureus: an emerging threatLancet Infect Dis200552758615854883
   PubMed Web of Science ®Google Scholar